Asthma Therapeutics Market Outlook, Strategies And Forecasts, Competitive analysis & Industry Trends

The research report identifies the key driving factors of the Asthma therapeutics market as the rising environmental pollution that adversely affects the respiratory system of the human body, causing asthma and other respiratory diseases. Rapidly growing industrialization and globalization have led to an imbalance in the environmental constitution.

One of the most conspicuous trends in this market is the adoption of a combination of therapies for the treatment of asthma patients. This technique can further help asthma patients by controlling inflammation caused in the respiratory tract. However, the biggest challenge faced by the drug producers is the etiology of respiratory diseases owing to which developing the remedy becomes a tough job.

Some of the key players of the global asthma therapeutics market are GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, AstraZeneca plc, and F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc (GSK) is the topmost seller of drugs of the of the global asthma therapeutics market. The British multinational company which was formed in 2000 is the largest drug and vaccine manufacturer for major diseases such as infections, digestive, asthma, mental health conditions, diabetes, and cancer.

Get a Free Sample Copy of the Report @

Advair – an eminent asthma therapeutic product is the highly selling drug which is manufactured by GlaxoSmithKline plc. After Advair, the Symbicort drug manufactured by AstraZeneca holds the second position in selling asthma drugs in the global asthma therapeutics market.

Table of Content

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Disease Introduction

2.2 Epidemiology

2.3 Etiology

2.4 Pathophysiology

2.5 Symptoms

2.6 Diagnosis

2.7 Assessment of Disease Severity

2.8 Treatment

2.9 Treatment Algorithm

2.10 Treatment Segments

2.10.1 ICS Monotherapy for the Maintenance Treatment of Asthma

2.10.2 Singulair (montelukast sodium) as First-Line Maintenance Therapy

2.10.3 ICS/LABA Combination Therapy

2.10.4 Add-on Therapies

3 Marketed Products

3.1 Overview

3.2 ICS for the Maintenance Treatment of Asthma

3.2.1 Arnuity (fluticasone furoate) – GSK

3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma

3.3.1 Advair (fluticasone propionate and salmeterol xinafoate) – GSK

3.3.2 Symbicort (budesonide and formoterol fumarate) – AstraZeneca, Co-Promotion with Astellas Pharma

3.3.3 Dulera (mometasone furoate and formoterol fumarate) – Merck

3.3.4 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) – GlaxoSmithKline/Theravance

3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma

3.4.1 Xolair (omalizumab) – Novartis and Genentech

3.4.2 Singulair (montelukast) – Merck

3.4.3 Spiriva (tiotropium bromide) – Boehringer Ingelheim

3.5 Heat Maps for Marketed Products